ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
15 hedge funds and large institutions have $6.69M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
150% more funds holding
Funds holding: 6 → 15 (+9)
69% more capital invested
Capital invested by funds: $3.95M → $6.69M (+$2.74M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$1.82M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$210K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$172K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$144K |
| 5 |
VF
Virtu Financial
New York
|
+$97.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$724K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$33K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7K |
ASLN Hedge Fund Activity: Q4 2019 in Review
15 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q4 2019, worth a combined $6.69M — up 69% from $3.95M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ASLN positions and 2 closed out — a net gain of 9 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.82M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $724K sold.
- 15 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q4 2019, up from 6 in Q3 2019.
- Funds reported $6.69M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q4 2019, up 69% quarter-over-quarter.
- 11 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q4 2019 and 2 closed out, a net change of +9 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q4 2019 was Sio Capital Management, an estimated $1.82M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q4 2019 was Baillie Gifford & Co, an estimated $724K sold.
Based on aggregated 13F filings for Q4 2019.